Approach to Suspected Primary Immunodeficiency in ICU

A Systematic Approach to Suspected Primary Immunodeficiency in Adult Critical Care Patients

Dr Neeraj Manikath, claude. ai

Abstract

Primary immunodeficiency disorders (PIDs) are increasingly recognized in adult populations, yet they remain underdiagnosed in critical care settings where they can present with severe, recurrent, or unusual infections. This review outlines a systematic diagnostic approach to suspected PIDs in adult critical care patients, emphasizing early recognition, appropriate laboratory evaluation, and timely intervention strategies. The approach integrates recent advances in molecular diagnostics with practical clinical considerations for the critical care physician.

Introduction

Primary immunodeficiency disorders (PIDs) encompass more than 450 genetically defined conditions that affect the development and/or function of the immune system[1]. While traditionally considered pediatric diseases, PIDs are increasingly diagnosed in adulthood, with nearly 40% of patients receiving their diagnosis after age 18[2]. The estimated prevalence of PIDs in the general population ranges from 1:1,200 to 1:10,000, but the true prevalence is likely higher due to underdiagnosis[3].

In critical care settings, undiagnosed PIDs may present as severe infections, sepsis with unusual pathogens, or multi-organ failure refractory to conventional therapy. Early recognition of PIDs in this population is crucial as it can significantly alter management strategies and improve outcomes[4]. However, the heterogeneity of PID presentations and the complexity of the critical care environment present diagnostic challenges.

This review provides a structured approach to recognizing and evaluating suspected PIDs in adult critical care patients, with emphasis on practical diagnostic algorithms, laboratory evaluation, and management principles.

Clinical Recognition: When to Suspect a PID

Warning Signs in Critical Care Settings

The following clinical scenarios should raise suspicion for an underlying PID in adult critical care patients:

1. Recurrent severe infections: Defined as ≥2 severe infections requiring hospitalization within one year[5].

2. Infections with opportunistic or unusual pathogens: Including Pneumocystis jirovecii, Cryptococcus, disseminated mycobacterial infection, or invasive Aspergillus[6].

3. Persistent infections despite appropriate antimicrobial therapy: Especially if the isolated pathogen demonstrates in vitro susceptibility[7].

4. Fulminant infections in previously healthy adults: Particularly with encapsulated bacteria (S. pneumoniae, H. influenzae, N. meningitidis)[8].

5. Family history of PIDs or unexplained early deaths: Suggesting inherited immune defects[9].

6. Autoimmune manifestations concurrent with infections: Common in certain PIDs like common variable immunodeficiency (CVID)[10].

The 10 Warning Signs Framework Adapted for Critical Care

Building on the Jeffrey Modell Foundation's 10 warning signs for PID[11], we propose the following adapted framework for critical care settings:

1. ≥2 episodes of sepsis within one year

2. ≥2 episodes of severe pneumonia within one year

3. Recurrent deep-seated abscesses requiring surgical drainage

4. Need for intravenous antibiotics to clear infections

5. Persistent fungemia or invasive fungal infections

6. Infections with unusual or opportunistic pathogens

7. Persistent laboratory evidence of inflammation despite appropriate therapy

8. Family history of immunodeficiency

9. Associated features suggesting immune dysregulation (e.g., autoimmunity, unexplained cytopenias)

10. Failure to thrive or chronic diarrhea in the absence of other causes

The presence of ≥2 of these signs warrants further immunological evaluation[12].

 Step-by-Step Diagnostic Approach

Step 1: Initial Assessment and Documentation

The first step involves a comprehensive review of the patient's history with particular attention to:

1. Detailed infection history: Type, frequency, severity, and causative pathogens of previous infections[13].

2. Family history: Construct a three-generation pedigree focusing on infections, early deaths, and known immunodeficiencies[14].

3. Medication review: Exclude secondary immunodeficiency due to immunosuppressive agents[15].

4. Physical examination: Document lymphoid tissue abnormalities, skin lesions, and anatomical factors that might predispose to infections[16].

Step 2: Pattern Recognition - Classifying the Suspected Immune Defect

Based on the presenting infections and clinical features, classify the suspected immune defect into one of the following categories:

1. Humoral (B-cell) immunity defects: Recurrent sinopulmonary infections, gastrointestinal infections, sepsis with encapsulated bacteria[17].

2. Cellular (T-cell) immunity defects: Viral infections, fungal infections, Pneumocystis pneumonia, mycobacterial infections[18].

3. Phagocyte defects: Recurrent skin/soft tissue infections, deep-seated abscesses, delayed wound healing[19].

4. Complement defects: Recurrent Neisseria infections, angioedema, systemic lupus erythematosus (SLE)-like illness[20].

5. Combined immunodeficiencies: Features of multiple immune system defects[21].

 Step 3: Initial Laboratory Evaluation

The first tier of laboratory investigations should include:

1. Complete blood count with differential: To evaluate for cytopenias, lymphopenia, or neutropenia[22].

2. Serum immunoglobulin levels (IgG, IgA, IgM, IgE): To assess humoral immunity[23].

3. Lymphocyte subset analysis: To quantify T cells (CD3+, CD4+, CD8+), B cells (CD19+), and NK cells (CD16+/CD56+)[24].

4. Complement studies: CH50, AP50, and individual complement components if indicated[25].

5. HIV testing: To exclude secondary immunodeficiency[26].

Table 1 summarizes the initial laboratory evaluation and normal reference ranges.

 Table 1: Initial Laboratory Evaluation for Suspected PID

| Test | Normal Range (Adult) | Significance if Abnormal |

|------|----------------------|--------------------------|

| Absolute lymphocyte count | 1,000-4,800 cells/μL | Lymphopenia suggests T-cell or combined immunodeficiency |

| Serum IgG | 700-1,600 mg/dL | Low: Antibody deficiency; High: Immune dysregulation |

| Serum IgA | 70-400 mg/dL | Low: Selective IgA deficiency, CVID |

| Serum IgM | 40-230 mg/dL | Low: CVID; High: Hyper-IgM syndrome |

| CD4+ T cells | 500-1,400 cells/μL | Low: Cellular immunodeficiency |

| CD19+ B cells | 100-500 cells/μL | Low: B-cell defects, CVID |

| CH50 | 42-95 U/mL | Low: Complement deficiency |

 Step 4: Functional and Specialized Testing

Based on the results of initial testing, proceed to second-tier investigations:

1. For suspected antibody deficiencies:

   - Specific antibody responses to protein and polysaccharide vaccines[27]

   - B-cell subset analysis (naïve, memory, transitional)[28]

   - In vitro B-cell function studies if available[29]

2. For suspected T-cell defects:

   - Lymphocyte proliferation assays in response to mitogens and antigens[30]

   - T-cell receptor excision circles (TRECs)[31]

   - Cytokine production assays[32]

3. For suspected phagocyte defects:

   - Neutrophil oxidative burst assay (dihydrorhodamine or nitroblue tetrazolium test)[33]

   - Chemotaxis assays[34]

   - Surface expression of adhesion molecules[35]

4. For suspected complement defects:

   - Targeted complement component assays based on CH50/AP50 results[36]

   - Functional complement pathway assessments[37]

Step 5: Genetic Testing

Genetic evaluation has become increasingly important in PID diagnosis:

1. Targeted gene sequencing: For patients with a specific suspected PID[38].

2. Next-generation sequencing panels: For PID-specific gene panels covering multiple potential genetic defects[39].

3. Whole exome or whole genome sequencing: For complicated cases without a clear diagnostic category[40].

Importantly, genetic testing should be performed in consultation with immunologists and genetic counselors, with consideration of the critical care context and timing[41].

Step 6: Multidisciplinary Discussion and Specialist Consultation

The final diagnostic step involves:

1. Discussion of findings with immunology specialists

2. Integration of results to establish a definitive diagnosis

3. Development of a targeted management plan based on the identified immune defect[42]

Management Principles in Critical Care

 Immediate Interventions

For critically ill patients with suspected or confirmed PID:

1. Targeted antimicrobial therapy:

   - Broad-spectrum coverage initially, with consideration of atypical and opportunistic pathogens[43]

   - Guided de-escalation based on cultures and clinical response[44]

   - Consider prophylactic antimicrobials for specific defects (e.g., Pneumocystis prophylaxis in T-cell defects)[45]

2. Immunoglobulin replacement therapy:

   - Consider emergency IVIg (0.4-0.6 g/kg) for patients with severe infections and suspected or confirmed antibody deficiencies[46]

   - Target trough IgG levels >700-800 mg/dL in critical illness[47]

3. Adjunctive therapies:

   - Granulocyte colony-stimulating factor (G-CSF) for severe neutropenia[48]

   - Granulocyte transfusions for life-threatening infections in phagocyte disorders[49]

   - Fresh frozen plasma for complement deficiencies with severe infections[50]

 

Long-term Considerations

Once stabilized, patients should be evaluated for:

1. Ongoing replacement therapy: Regular immunoglobulin replacement for antibody deficiencies[51]

2. Antimicrobial prophylaxis: Based on the specific immune defect[52]

3. Hematopoietic stem cell transplantation (HSCT): Definitive therapy for selected severe PIDs[53]

4. Gene therapy: Emerging option for specific genetic defects[54]

5.  Immune modulatory therapies: For PIDs with immune dysregulation features[55]

Case Vignettes

The following case vignettes illustrate the application of the diagnostic approach:

Case 1: Recurrent Pneumococcal Sepsis

A 42-year-old woman presents with her third episode of pneumococcal sepsis in 18 months. She has no significant past medical history apart from recurrent sinusitis.

Diagnostic Approach:

- Initial testing reveals low IgG (380 mg/dL) and IgA (<10 mg/dL) with normal IgM and lymphocyte subsets

- Vaccine challenge shows poor response to pneumococcal polysaccharide vaccine

- Diagnosis: Common Variable Immunodeficiency (CVID)

- Management: IVIg therapy (0.4-0.6 g/kg monthly), antimicrobial prophylaxis

 Case 2: Invasive Aspergillosis

A 36-year-old man is admitted with invasive pulmonary aspergillosis. History reveals childhood pneumonias and persistent oral candidiasis.

Diagnostic Approach:

- Initial testing shows lymphopenia with markedly reduced CD4+ T cells (120 cells/μL)

- HIV testing negative

- Genetic testing reveals a STAT3 gain-of-function mutation

- Diagnosis: STAT3 Gain-of-Function Immune Dysregulation Syndrome

- Management: Antifungal therapy, antimicrobial prophylaxis, consideration of targeted JAK inhibition

Conclusion

Primary immunodeficiencies represent an important consideration in adult critical care patients with unusual, severe, or recurrent infections. The systematic approach outlined in this review provides a framework for timely recognition, appropriate diagnostic evaluation, and targeted management of these conditions in the critical care setting. Early involvement of immunology specialists and a multidisciplinary approach are essential for optimal outcomes.

As advances in genetic technology continue to expand our understanding of PIDs, the critical care physician should maintain a high index of suspicion for these disorders and be familiar with the basic diagnostic pathway. Future directions include point-of-care genetic testing, improved biomarkers for early PID detection, and novel targeted immunomodulatory therapies.

References

1. Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473-1507.

2. Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2018;38(1):129-143.

3. Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34(8):954-961.

4. Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med. 2015;3(8):651-660.

5. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.e1-78.

6. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007;166(11):1099-1117.

7. Sobh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(6):1066-1075.

8. Picard C, Puel A, Bustamante J, et al. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol. 2003;3(6):451-459.

9. Meyts I, Bosch B, Bolze A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138(4):957-969.

10. Gathmann B, Mahlaoui N, Gérard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116-126.

11. O'Sullivan MD, Cant AJ. The 10 warning signs: a time for a change? Curr Opin Allergy Clin Immunol. 2012;12(6):588-594.

12. Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1-7.

13. Reust CE. Evaluation of primary immunodeficiency disease in children. Am Fam Physician. 2013;87(11):773-778.

14. Modell V, Orange JS, Quinn J, Modell F. Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes. Immunol Res. 2018;66(3):367-380.

15. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203-211.

16. Grimbacher B, Schaffer AA, Holland SM, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65(3):735-744.

17. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709-727.

18. Notarangelo LD. Functional T cell immunodeficiencies (with T cells present). Annu Rev Immunol. 2013;31:195-225.

19. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010;38(1):3-10.

20. Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states and associated infections. Mol Immunol. 2011;48(14):1643-1655.

21. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:15061.

22. Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S297-S305.

23. Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99(3):281-283.

24. Abraham RS, Aubert G. Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies. Clin Vaccine Immunol. 2016;23(4):254-271.

25. Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem. 2016;77:1-75.

26. Hoffman TW, van Kessel DA, Rijkers GT. Impact of Using Different Response Criteria for Pneumococcal Polysaccharide Vaccination for Assessment of Humoral Immune Status. J Clin Immunol. 2018;38(2):149-158.

27. Yazdani R, Abolhassani H, Asgardoon MH, et al. Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders. J Investig Allergol Clin Immunol. 2017;27(4):213-224.

28. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77-85.

29. Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematology Am Soc Hematol Educ Program. 2012;2012:301-305.

30. Lehman HK, Ballow M. Immune deficiency disorders with autoimmunity and abnormalities in immune regulation-monogenic autoimmune diseases. Clin Rev Allergy Immunol. 2008;34(2):141-145.

31. Baker MW, Grossman WJ, Laessig RH, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124(3):522-527.

32. Orange JS. Congenital natural killer cell deficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):399-409.

33. Yu JE, Azar AE, Chong HJ, Jongco AM 3rd, Prince BT. Considerations in the Diagnosis of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S6-S11.

34. van de Vosse E, van Dissel JT, Holland SM. Invasive fungal infections in patients with chronic granulomatous disease. Adv Exp Med Biol. 2009;634:27-43.

35. Dinauer MC. Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program. 2005:89-95.

36. Brodszki N, Frazer-Abel A, Grumach AS, et al. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. J Clin Immunol. 2020;40(4):576-591.

37. Lewis EM, Singla M, Sergeant S, Koty PP, McPhail LC. X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation. Clin Immunol. 2008;129(2):372-380.

38. Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev. 2019;287(1):241-252.

39. Seleman M, Hoyos-Bachiloglu R, Geha RS, Chou J. Uses of Next-Generation Sequencing Technologies for the Diagnosis of Primary Immunodeficiencies. Front Immunol. 2017;8:847.

40. Rae W, Ward D, Mattocks C, et al. Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics. Clin Genet. 2018;93(3):647-655.

41. Gallo V, Dotta L, Giardino G, et al. Diagnostics of Primary Immunodeficiencies through Next-Generation Sequencing. Front Immunol. 2016;7:466.

42. Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol. 2010;135(2):204-209.

43. Schwartz SA. The many faces of acquired immune deficiency syndrome. JAMA. 1987;258(14):1946-1947.

44. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol. 2008;30(3):209-235.

45. Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176-1183.

46. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1-S46.

47. Ramzi N, Jamee M, Bakhtiyari M, et al. Bronchiectasis in common variable immunodeficiency: A systematic review and meta-analysis. Pediatr Pulmonol. 2020;55(2):292-299.

48. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S195-S203.

49. Heimall J, Logan BR, Cowan MJ, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130(25):2718-2727.

50. King J, Patel M, Ramesh M, et al. IgE-mediated drug allergy in patients with primary immunodeficiency. J Allergy Clin Immunol Pract. 2021;9(1):478-480.

51. Shillitoe B, Bangs C, Guzman D, et al. The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017. Clin Exp Immunol. 2018;192(3):284-291.

52. Thaunat O, Morelon E. Cancer immunosurveillance: missing in action after organ transplantation? Am J Transplant. 2014;14(7):1484-1485.

53. Abolhassani H, Hammarström L, Cunningham-Rundles C. Current genetic landscape in common variable immune deficiency. Blood. 2020;135(9):656-667.

54. Booth C, Gaspar HB, Thrasher AJ. Gene therapy for primary immunodeficiency. Curr Opin Pediatr. 2011;23(6):659-666.

55. Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: An expanding universe. Sci Immunol. 2020;5(49):eabb1662.